Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Apremilast · Otezla

Small molecule · Inhibitor of phosphodiesterase 4 · developed by Amgen

Approved FDA, Mar 2014
AMGN Developer
2 Registered trials

What is Apremilast?

Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) that increases intracellular cAMP levels.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Otezla
Drug type
Small molecule
Targets
phosphodiesterase 4
Mechanism
Inhibitor of phosphodiesterase 4
Pathways
cAMP signaling
Therapy area
Dermatology, Immunology, Musculoskeletal
Developer
Amgen Inc (AMGN)
FDA status
Approved as Otezla (March 21, 2014), NDA205437 · FDA label
UNII
N5UK68MGDZ

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 2, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03747939 Phase 4 Arthritis, Psoriatic Completed AMGN
NCT04804553 Phase 3 Active Juvenile Psoriatic Arthritis Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Active Juvenile Psoriatic ArthritisArthritis, Psoriatic

More from Amgen

Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Apremilast

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.